Work

1840eP Durvalumab and copanlisib combination in unresectable stage III NSCLC consolidation with exceptional PFS

Year: 2025

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.08.2463

Authors: Z. Hao, S.M. Arnold, J. Kolesar, H. Weiss, J. Wu

Institutions: University of Kentucky, Markey Cancer Center, University of New Mexico

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415940429

FWCI:

Cites:

Cited by:

Related to: 10